Study guide

17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment

Key Takeaways Explain This Topic AI

Autosomal dominant conditions (BRCA, Lynch, familial hypercholesterolemia) give each child a 50% risk; when both parents carry an autosomal recessive condition (CF, SMA, sickle cell), each child has a 25% risk of being affected.

In X-linked recessive disorders such as hemophilia and Duchenne muscular dystrophy, a carrier mother passes the condition to half her sons and carrier status to half her daughters; an affected father has no affected sons and all carrier daughters.

An FMR1 premutation (55–200 CGG repeats) causes primary ovarian insufficiency in about 20% of female carriers and can expand to a full mutation (>200) when passed through a mother.

The USPSTF recommends that women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or Ashkenazi Jewish ancestry, be assessed with a brief risk tool and referred for genetic counseling if positive.

The Genetic Information Nondiscrimination Act (2008) protects against discrimination in health insurance and employment, but not in life, disability, or long-term care insurance.

Last updated: October 2026

Patterns of Inheritance

Pattern Transmission Examples

Autosomal dominant One altered copy causes the trait; each child of an affected parent has a 50% risk ; males and females equally affected; appears in every generation (variable penetrance) BRCA1/2, Lynch syndrome, familial hypercholesterolemia, Marfan syndrome, Huntington disease

Autosomal recessive Two altered copies needed; two carrier parents: 25% affected, 50% carriers, 25% unaffected noncarriers per pregnancy; often no family history; more common with consanguinity Cystic fibrosis, spinal muscular atrophy, sickle cell disease, thalassemias, Tay-Sachs disease

X-linked recessive Carrier mother: 50% of sons affected, 50% of daughters carriers ; affected father: all daughters carriers, no sons affected (no male-to-male transmission) Hemophilia A and B, Duchenne muscular dystrophy, G6PD deficiency

X-linked dominant Affected father passes it to all daughters and no sons Fragile X (with anticipation), vitamin D–resistant rickets

Mitochondrial Passed only through the mother to all her children MELAS, Leber hereditary optic neuropathy

Multifactorial Genes plus environment; recurrence about 2%–5% after one affected child Neural tube defects, cleft lip and palate, many congenital heart defects

Chromosomal Nondisjunction (risk rises with maternal age), translocations, deletions Trisomies 21, 18, and 13; Turner syndrome; 22q11.2 deletion; a balanced Robertsonian translocation causes familial Down syndrome

Fragile X and the FMR1 Gene

  • CGG Repeats Category Significance
  • Fewer than 45 Normal —
  • 45–54 Intermediate Small expansion risk

55–200 Premutation Primary ovarian insufficiency in about 20% of female carriers; tremor/ataxia syndrome in older carriers; can expand to a full mutation when passed by a mother

More than 200 Full mutation Fragile X syndrome (most common inherited intellectual disability)

ACOG recommends fragile X carrier testing for people with a family history of fragile X or unexplained intellectual disability and for women with unexplained POI or elevated FSH before 40.

Carrier Screening Strategy

Offer to everyone considering pregnancy or currently pregnant (ACOG): cystic fibrosis and spinal muscular atrophy, plus a CBC (with hemoglobin electrophoresis based on indices and ancestry) for hemoglobinopathies.

Ancestry-based panels (for example, Ashkenazi Jewish: Tay-Sachs, Canavan, familial dysautonomia) or expanded panels for everyone are both acceptable. ACMG (2021) recommends a tiered expanded panel for all.

If one partner is a carrier, offer testing to the reproductive partner promptly; if both are carriers, refer to genetic counseling to discuss prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing in future IVF.

Explain residual risk : a negative screen lowers but does not eliminate carrier probability.

Prenatal aneuploidy screening and diagnostic testing are covered in the obstetric diagnostics section.

  • Hereditary Cancer Risk Assessment
  • USPSTF (2019, Grade B)

Assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer , or an ancestry associated with BRCA1/2 variants (such as Ashkenazi Jewish), with a brief familial risk tool : the Ontario Family History Assessment Tool, Manchester Scoring System, Referral Screening Tool, Pedigree Assessment Tool, 7-Question Family History Screen, or the Tyrer-Cuzick (IBIS) model. A positive result leads to genetic counseling , then testing if indicated. Routine assessment, counseling, or testing is not recommended for women without these histories (grade D).

Red Flags for Genetic Referral

Breast cancer at 50 or younger , triple-negative breast cancer at 60 or younger, or bilateral or multiple primary cancers.

Ovarian, tubal, or peritoneal cancer at any age.

Male breast cancer , pancreatic cancer, or metastatic prostate cancer in the family.

Two or more relatives on the same side with breast, ovarian, pancreatic, or prostate cancer.

Ashkenazi Jewish ancestry with any of these cancers.

A known pathogenic variant in the family.

Lynch indicators: colorectal or endometrial cancer before 50, a mismatch-repair–deficient tumor, or the Amsterdam II "3-2-1" pattern (three relatives with Lynch cancers, two generations, one diagnosed before 50).

Cancer Risks and Management

Syndrome Key Risks Risk-Reducing Management

BRCA1 Breast about 55%–72% lifetime; ovarian about 39%–44% Annual breast MRI from 25 , mammography from 30 (often alternating every 6 months); risk-reducing salpingo-oophorectomy (RRSO) at 35–40 after childbearing; consider risk-reducing mastectomy

BRCA2 Breast about 45%–69%; ovarian about 11%–17% Same screening; RRSO at 40–45

Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) Colorectal and endometrial (up to roughly 40%–60% depending on the gene), ovarian, and others Colonoscopy every 1–2 years from 20–25 ; hysterectomy with BSO after childbearing (often in the 40s)

Li-Fraumeni (TP53) Very early breast cancer, sarcomas, brain tumors MRI-based screening; avoid radiation when possible

Cowden (PTEN) Breast, thyroid, and endometrial cancers Enhanced screening

PALB2, CDH1, and others Elevated breast risk; CDH1 adds diffuse gastric cancer and lobular breast cancer Gene-specific plans

Combined oral contraceptives lower ovarian cancer risk in BRCA carriers and can be used for contraception.

Chemoprevention (USPSTF 2019, Grade B)

Offer risk-reducing medications to women at increased breast cancer risk (for example, a 5-year risk of 3% or higher) with low adverse-effect risk:

Tamoxifen (premenopausal or postmenopausal): Increases VTE, endometrial cancer, and cataracts.

Raloxifene (postmenopausal): Increases VTE but not endometrial cancer, and protects bone.

Aromatase inhibitors (postmenopausal): Cause bone loss and arthralgias.

Ethics and Privacy of Genetic Information

Pretest counseling covers benefits, limitations, possible variants of uncertain significance, and implications for relatives; post-test counseling covers cascade testing of family members.

The Genetic Information Nondiscrimination Act (GINA, 2008) prohibits genetic discrimination in health insurance and employment (for employers with 15 or more employees), but not in life, disability, or long-term care insurance.

Direct-to-consumer tests may check only a few variants (for example, three Ashkenazi founder BRCA variants) and should not replace clinical testing when the history is concerning.